SMYD2 has oncogenic properties by repressing the activity of p53 and RB through methylation [47, 48] and SMYD3 is commonly upregulated in hepatocellular carcinoma, colon carcinoma and breast cancer with influence on cell proliferation in vitro [49–52]. Here, SMYD2 is linked to breast carcinoma.